These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Inhibition of mast cells: a novel mechanism by which nintedanib may elicit anti-fibrotic effects. Overed-Sayer C; Miranda E; Dunmore R; Liarte Marin E; Beloki L; Rassl D; Parfrey H; Carruthers A; Chahboub A; Koch S; Güler-Gane G; Kuziora M; Lewis A; Murray L; May R; Clarke D Thorax; 2020 Sep; 75(9):754-763. PubMed ID: 32709610 [TBL] [Abstract][Full Text] [Related]
4. Biochanin-A ameliorates pulmonary fibrosis by suppressing the TGF-β mediated EMT, myofibroblasts differentiation and collagen deposition in in vitro and in vivo systems. Andugulapati SB; Gourishetti K; Tirunavalli SK; Shaikh TB; Sistla R Phytomedicine; 2020 Nov; 78():153298. PubMed ID: 32781391 [TBL] [Abstract][Full Text] [Related]
5. Nintedanib reduces ventilation-augmented bleomycin-induced epithelial-mesenchymal transition and lung fibrosis through suppression of the Src pathway. Li LF; Kao KC; Liu YY; Lin CW; Chen NH; Lee CS; Wang CW; Yang CT J Cell Mol Med; 2017 Nov; 21(11):2937-2949. PubMed ID: 28598023 [TBL] [Abstract][Full Text] [Related]
6. Anlotinib attenuated bleomycin-induced pulmonary fibrosis via the TGF-β1 signalling pathway. Ruan H; Lv Z; Liu S; Zhang L; Huang K; Gao S; Gan W; Liu X; Zhang S; Helian K; Li X; Zhou H; Yang C J Pharm Pharmacol; 2020 Jan; 72(1):44-55. PubMed ID: 31659758 [TBL] [Abstract][Full Text] [Related]
7. TNF-α-induced NF-κB activation promotes myofibroblast differentiation of LR-MSCs and exacerbates bleomycin-induced pulmonary fibrosis. Hou J; Ma T; Cao H; Chen Y; Wang C; Chen X; Xiang Z; Han X J Cell Physiol; 2018 Mar; 233(3):2409-2419. PubMed ID: 28731277 [TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and discovery of 2(1H)-quinolone derivatives for the treatment of pulmonary fibrosis through inhibition of TGF-β/smad dependent and independent pathway. Xue L; Deng D; Zheng S; Tang M; Yang Z; Pei H; Chen Y; Yang T; Liu K; Ye H; Chen L Eur J Med Chem; 2020 Jul; 197():112259. PubMed ID: 32334267 [TBL] [Abstract][Full Text] [Related]
9. Novel Mechanisms for the Antifibrotic Action of Nintedanib. Rangarajan S; Kurundkar A; Kurundkar D; Bernard K; Sanders YY; Ding Q; Antony VB; Zhang J; Zmijewski J; Thannickal VJ Am J Respir Cell Mol Biol; 2016 Jan; 54(1):51-9. PubMed ID: 26072676 [TBL] [Abstract][Full Text] [Related]
10. Induced pluripotent stem cell-derived mesenchymal stem cells reverse bleomycin-induced pulmonary fibrosis and related lung stiffness. Chakraborty A; Wang C; Hodgson-Garms M; Broughton BRS; Frith JE; Kelly K; Samuel CS Biomed Pharmacother; 2024 Sep; 178():117259. PubMed ID: 39116786 [TBL] [Abstract][Full Text] [Related]
11. Nintedanib inhibits epithelial-mesenchymal transition in A549 alveolar epithelial cells through regulation of the TGF-β/Smad pathway. Ihara H; Mitsuishi Y; Kato M; Takahashi F; Tajima K; Hayashi T; Hidayat M; Winardi W; Wirawan A; Hayakawa D; Kanamori K; Matsumoto N; Yae T; Sato T; Sasaki S; Takamochi K; Suehara Y; Ogura D; Niwa SI; Suzuki K; Takahashi K Respir Investig; 2020 Jul; 58(4):275-284. PubMed ID: 32359980 [TBL] [Abstract][Full Text] [Related]
12. Adipose-derived mesenchymal stem cell therapy for reverse bleomycin-induced experimental pulmonary fibrosis. Zhao X; Wu J; Yuan R; Li Y; Yang Q; Wu B; Zhai X; Wang J; Magalon J; Sabatier F; Daumas A; Zhu WM; Zhu N Sci Rep; 2023 Aug; 13(1):13183. PubMed ID: 37580529 [TBL] [Abstract][Full Text] [Related]
13. Effects and mechanisms of pirfenidone, prednisone and acetylcysteine on pulmonary fibrosis in rat idiopathic pulmonary fibrosis models. Yu W; Guo F; Song X Pharm Biol; 2017 Dec; 55(1):450-455. PubMed ID: 27937011 [TBL] [Abstract][Full Text] [Related]
14. Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis. Wollin L; Maillet I; Quesniaux V; Holweg A; Ryffel B J Pharmacol Exp Ther; 2014 May; 349(2):209-20. PubMed ID: 24556663 [TBL] [Abstract][Full Text] [Related]
15. Dual inhibition of α Decaris ML; Schaub JR; Chen C; Cha J; Lee GG; Rexhepaj M; Ho SS; Rao V; Marlow MM; Kotak P; Budi EH; Hooi L; Wu J; Fridlib M; Martin SP; Huang S; Chen M; Muñoz M; Hom TF; Wolters PJ; Desai TJ; Rock F; Leftheris K; Morgans DJ; Lepist EI; Andre P; Lefebvre EA; Turner SM Respir Res; 2021 Oct; 22(1):265. PubMed ID: 34666752 [TBL] [Abstract][Full Text] [Related]
16. Hypoxia-preconditioned mesenchymal stem cells attenuate bleomycin-induced pulmonary fibrosis. Lan YW; Choo KB; Chen CM; Hung TH; Chen YB; Hsieh CH; Kuo HP; Chong KY Stem Cell Res Ther; 2015 May; 6(1):97. PubMed ID: 25986930 [TBL] [Abstract][Full Text] [Related]
17. MAP3K19 Is a Novel Regulator of TGF-β Signaling That Impacts Bleomycin-Induced Lung Injury and Pulmonary Fibrosis. Boehme SA; Franz-Bacon K; DiTirro DN; Ly TW; Bacon KB PLoS One; 2016; 11(5):e0154874. PubMed ID: 27144281 [TBL] [Abstract][Full Text] [Related]
18. Andrographolide ameliorates bleomycin-induced pulmonary fibrosis by suppressing cell proliferation and myofibroblast differentiation of fibroblasts via the TGF-β1-mediated Smad-dependent and -independent pathways. Li J; Feng M; Sun R; Li Z; Hu L; Peng G; Xu X; Wang W; Cui F; Yue W; He J; Liu J Toxicol Lett; 2020 Mar; 321():103-113. PubMed ID: 31706003 [TBL] [Abstract][Full Text] [Related]
19. Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis. Hostettler KE; Zhong J; Papakonstantinou E; Karakiulakis G; Tamm M; Seidel P; Sun Q; Mandal J; Lardinois D; Lambers C; Roth M Respir Res; 2014 Dec; 15(1):157. PubMed ID: 25496490 [TBL] [Abstract][Full Text] [Related]
20. Soluble epoxide hydrolase inhibitor AUDA decreases bleomycin-induced pulmonary toxicity in mice by inhibiting the p38/Smad3 pathways. Dong XW; Jia YL; Ge LT; Jiang B; Jiang JX; Shen J; Jin YC; Guan Y; Sun Y; Xie QM Toxicology; 2017 Aug; 389():31-41. PubMed ID: 28694203 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]